Complete response and overall survival: univariate analyses
| Factor . | Age < 60 (n = 653) . | . | Age ≥ 60 (n = 664) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CR . | Median survival . | . | CR . | Median survival . | |||||||
| N . | N (%) . | P* . | Weeks . | P† . | . | N . | N (%) . | P* . | Weeks . | P† . | |
| Diagnosis to treatment interval, d | |||||||||||
| 1 | 102 | 76 (75) | 81.0 | 76 | 47 (62) | 26.0 | |||||
| 2 | 99 | 75 (76) | 85.0 | 79 | 43 (54) | 28.0 | |||||
| 3 | 97 | 71 (73) | 100.0 | 82 | 48 (59) | 34.0 | |||||
| 4 | 85 | 60 (71) | 104.0 | 76 | 38 (50) | 31.0 | |||||
| 5-6 | 93 | 60 (65) | 69.0 | 95 | 52 (54) | 35.0 | |||||
| 7-10 | 86 | 52 (60) | 60.0 | 135 | 71 (53) | 39.0 | |||||
| > 10 | 91 | 45 (49) | < .001 | 50.0 | .04 | 121 | 63 (52) | .19 | 35.0 | .15 | |
| Treated as a continuous variable‡ | < .001 | < .001 | .45 | .19 | |||||||
| WBC, per mm3 | |||||||||||
| < 1.5 | 89 | 55 (62) | 64.0 | 116 | 68 (59) | 38.0 | |||||
| 1.5-< 2.5 | 84 | 51 (61) | 63.0 | 119 | 79 (66) | 43.0 | |||||
| 2.5-< 4.0 | 92 | 61 (66) | 66.0 | 94 | 54 (57) | 38.0 | |||||
| 4.0-< 8.0 | 112 | 86 (77) | 99.0 | 105 | 54 (51) | 31.0 | |||||
| 8.0-< 14.0 | 92 | 61 (66) | 62.0 | 80 | 34 (43) | 19.0 | |||||
| 14.0-< 25.0 | 89 | 58 (65) | 104.0 | 73 | 40 (55) | 35.0 | |||||
| > 25.0 | 95 | 67 (71) | .19 | 67.0 | .47 | 77 | 33 (43) | .001 | 26.0 | .03 | |
| Treated as a continuous variable‡ | .67 | .89 | .008 | .03 | |||||||
| Etiology | |||||||||||
| De novo | 414 | 321 (78) | 89.0 | 314 | 179 (57) | 32.0 | |||||
| Secondary | 239 | 118 (49) | < .001 | 50.0 | < .001 | 350 | 183 (52) | .22 | 34.0 | .91 | |
| Age, y | |||||||||||
| < 30 | 88 | 74 (84) | 123.0 | 60-62 | 114 | 72 (63) | 37.0 | ||||
| 31-40 | 100 | 78 (78) | 192.0 | 63-65 | 93 | 52 (56) | 32.0 | ||||
| 41-45 | 88 | 59 (67) | 89.0 | 66-68 | 112 | 62 (55) | 29.0 | ||||
| 46-50 | 104 | 62 (60) | 60.0 | 69-71 | 125 | 67 (54) | 36.0 | ||||
| 51-55 | 136 | 88 (65) | 59.0 | 72-75 | 108 | 53 (49) | 30.0 | ||||
| > 55 | 137 | 78 (57) | < .001 | 50.0 | < .001 | > 75 | 112 | 56 (50) | .02 | 25.0 | .01 |
| Treated as a continuous variable‡ | .009 | < .001 | .02 | .004 | |||||||
| Performance status | |||||||||||
| 0 | 96 | 63 (66) | 153.0 | 67 | 43 (64) | 82.0 | |||||
| 1 | 365 | 249 (68) | 71.0 | 345 | 194 (56) | 36.0 | |||||
| 2 | 76 | 42 (55) | 42.0 | 119 | 52 (44) | 17.0 | |||||
| 3-4 | 20 | 9 (45) | .03 | 13.0 | < .001 | 34 | 11 (32) | < .001 | 4.0 | < .001 | |
| Cytogenetics | |||||||||||
| Favorable | 82 | 78 (95) | Not reached | 23 | 20 (87) | 78.0 | |||||
| Intermediate | 425 | 302 (71) | 84.0 | 449 | 270 (60) | 43.0 | |||||
| Unfavorable | 146 | 59 (40) | < .001 | 25.0 | < .001 | 192 | 72 (38) | < .001 | 17.0 | < .001 | |
| Cytarabine dose | |||||||||||
| Conventional | 113 | 80 (71) | 92.0 | 147 | 95 (65) | 39.0 | |||||
| Mid-dose CI | 266 | 177 (67) | 66.0 | 224 | 107 (48) | 28.0 | |||||
| Mid- to high-dose bolus | 273 | 182 (67) | .51 | 67.0 | .69 | 289 | 158 (55) | .15 | 35.0 | .56 | |
| Factor . | Age < 60 (n = 653) . | . | Age ≥ 60 (n = 664) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CR . | Median survival . | . | CR . | Median survival . | |||||||
| N . | N (%) . | P* . | Weeks . | P† . | . | N . | N (%) . | P* . | Weeks . | P† . | |
| Diagnosis to treatment interval, d | |||||||||||
| 1 | 102 | 76 (75) | 81.0 | 76 | 47 (62) | 26.0 | |||||
| 2 | 99 | 75 (76) | 85.0 | 79 | 43 (54) | 28.0 | |||||
| 3 | 97 | 71 (73) | 100.0 | 82 | 48 (59) | 34.0 | |||||
| 4 | 85 | 60 (71) | 104.0 | 76 | 38 (50) | 31.0 | |||||
| 5-6 | 93 | 60 (65) | 69.0 | 95 | 52 (54) | 35.0 | |||||
| 7-10 | 86 | 52 (60) | 60.0 | 135 | 71 (53) | 39.0 | |||||
| > 10 | 91 | 45 (49) | < .001 | 50.0 | .04 | 121 | 63 (52) | .19 | 35.0 | .15 | |
| Treated as a continuous variable‡ | < .001 | < .001 | .45 | .19 | |||||||
| WBC, per mm3 | |||||||||||
| < 1.5 | 89 | 55 (62) | 64.0 | 116 | 68 (59) | 38.0 | |||||
| 1.5-< 2.5 | 84 | 51 (61) | 63.0 | 119 | 79 (66) | 43.0 | |||||
| 2.5-< 4.0 | 92 | 61 (66) | 66.0 | 94 | 54 (57) | 38.0 | |||||
| 4.0-< 8.0 | 112 | 86 (77) | 99.0 | 105 | 54 (51) | 31.0 | |||||
| 8.0-< 14.0 | 92 | 61 (66) | 62.0 | 80 | 34 (43) | 19.0 | |||||
| 14.0-< 25.0 | 89 | 58 (65) | 104.0 | 73 | 40 (55) | 35.0 | |||||
| > 25.0 | 95 | 67 (71) | .19 | 67.0 | .47 | 77 | 33 (43) | .001 | 26.0 | .03 | |
| Treated as a continuous variable‡ | .67 | .89 | .008 | .03 | |||||||
| Etiology | |||||||||||
| De novo | 414 | 321 (78) | 89.0 | 314 | 179 (57) | 32.0 | |||||
| Secondary | 239 | 118 (49) | < .001 | 50.0 | < .001 | 350 | 183 (52) | .22 | 34.0 | .91 | |
| Age, y | |||||||||||
| < 30 | 88 | 74 (84) | 123.0 | 60-62 | 114 | 72 (63) | 37.0 | ||||
| 31-40 | 100 | 78 (78) | 192.0 | 63-65 | 93 | 52 (56) | 32.0 | ||||
| 41-45 | 88 | 59 (67) | 89.0 | 66-68 | 112 | 62 (55) | 29.0 | ||||
| 46-50 | 104 | 62 (60) | 60.0 | 69-71 | 125 | 67 (54) | 36.0 | ||||
| 51-55 | 136 | 88 (65) | 59.0 | 72-75 | 108 | 53 (49) | 30.0 | ||||
| > 55 | 137 | 78 (57) | < .001 | 50.0 | < .001 | > 75 | 112 | 56 (50) | .02 | 25.0 | .01 |
| Treated as a continuous variable‡ | .009 | < .001 | .02 | .004 | |||||||
| Performance status | |||||||||||
| 0 | 96 | 63 (66) | 153.0 | 67 | 43 (64) | 82.0 | |||||
| 1 | 365 | 249 (68) | 71.0 | 345 | 194 (56) | 36.0 | |||||
| 2 | 76 | 42 (55) | 42.0 | 119 | 52 (44) | 17.0 | |||||
| 3-4 | 20 | 9 (45) | .03 | 13.0 | < .001 | 34 | 11 (32) | < .001 | 4.0 | < .001 | |
| Cytogenetics | |||||||||||
| Favorable | 82 | 78 (95) | Not reached | 23 | 20 (87) | 78.0 | |||||
| Intermediate | 425 | 302 (71) | 84.0 | 449 | 270 (60) | 43.0 | |||||
| Unfavorable | 146 | 59 (40) | < .001 | 25.0 | < .001 | 192 | 72 (38) | < .001 | 17.0 | < .001 | |
| Cytarabine dose | |||||||||||
| Conventional | 113 | 80 (71) | 92.0 | 147 | 95 (65) | 39.0 | |||||
| Mid-dose CI | 266 | 177 (67) | 66.0 | 224 | 107 (48) | 28.0 | |||||
| Mid- to high-dose bolus | 273 | 182 (67) | .51 | 67.0 | .69 | 289 | 158 (55) | .15 | 35.0 | .56 | |
NA indicates not applicable.
χ2 test for factors with 2 levels, Cochran-Armitage trend test if more than 2 levels.
Log-rank test for factors with 2 levels, log-logistic model if more than 2 levels.
P values are from logistic (CR) and log-logistic (survival) models using the original, untransformed data.